Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

Recruiting

Phase 1

Phase 2

Dose-escalation Study to Evaluate the Safety and Tolerability of GS030 in Subjects With Retinitis Pigmentosa

Sponsor:

GenSight Biologics

Code:

NCT03326336

Conditions

Non-syndromic Retinitis Pigmentosa

Eligibility Criteria

Sex: All

Age: 18 - 70+

Healthy Volunteers: Not accepted

Interventions

Gene therapy: GS030-DP AND Medical device: GS030-MD

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-07-16. This information was provided to ClinicalTrials.gov by GenSight Biologics on 2022-07-26.